Market Overview

Roth Capital Upgraded Peregrine Pharma Following Internal Review of Trial

Share:
Related PPHM
Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma

Roth Capital upgraded Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) following news of an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled trial of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients.

The firm raised its rating from Neutral to Buy and boosted its price target from $1.25 to $2.70.

Latest Ratings for PPHM

DateFirmActionFromTo
Mar 2014McNicoll Lewis VlakMaintainsBuy
Mar 2013Piper JaffrayInitiates Coverage onOverweight
Jan 2013Roth CapitalUpgradesNeutralBuy

View More Analyst Ratings for PPHM
View the Latest Analyst Ratings

Posted-In: News Upgrades Analyst Ratings

 

Related Articles (PPHM)

View Comments and Join the Discussion!

Get Benzinga's Newsletters